Results 191 to 200 of about 384,012 (260)

Characteristics and Prognosis of Wild-Type Transthyretin Amyloid Cardiomyopathy Patients Diagnosed Before 65 Years Old. [PDF]

JACC Adv
Guijarro D, Eicher JC, Bézard M, Piriou N, Sauer F, Roubille F, Costa J, Réant P, Donal E, Bauer F, Bisson A, Bouchot O, Cariou E, Lairez O, Courand PY, Dagrenat C, Gueffet JP, Habib G, Jeanneteau J, Margerit L, Oghina S, Trésorier R, Kharoubi M, Damy T.   +23 more
europepmc   +1 more source

Safety and Efficacy of Tafamidis in Chinese Patients with Transthyretin Amyloid Cardiomyopathy. [PDF]

Cardiol Ther
Tian Z, Peng D, Ma W, Yan J, Wang J, Tang Y, Jin W, Liu Y, Jia C, Gao Y, Gong Y, Sun X, Chen N, Zhu S, Zhang S.   +14 more
europepmc   +1 more source

Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension.

JAMA Cardiol
Alexander KM, Davis MK, Akinboboye O, Berk J, Bhatt K, Cappelli F, Cuddy SAM, Fontana M, Garcia-Pavia P, Gillmore JD, Griffin JM, Grodin JL, Judge DP, Khouri MG, Lam K, Masri A, Maurer MS, Obici L, Ruberg FL, Sarswat N, Shah K, Soman P, Stern L, Wright R, Xiong K, Cao X, Lystig T, Tamby JF, Castaño A, Katz L, Sinha U, Fox JC, Solomon SD, Grogan M.   +33 more
europepmc   +1 more source

Influence of Age at Diagnosis on Clinical Disease Parameters in Wild-Type Transthyretin Amyloid Cardiomyopathy. [PDF]

JACC Asia
Kuyama N, Izumiya Y, Takashio S, Usuku H, Tabira A, Ishii M, Kidoh M, Oda S, Hanatani S, Matsuzawa Y, Yamamoto E, Hirai T, Ueda M, Tsujita K.   +13 more
europepmc   +1 more source

Silencers versus stabilizers in amyloid cardiomyopathy. Are we asking the wrong questions? [PDF]

Eur J Heart Fail
Falk RH, Cuddy SAM, Itzhaki Ben Zadok O.
europepmc   +1 more source

Reply: Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy. [PDF]

JACC Adv
Jaiswal V, Hanif M, Mashkoor Y, Prasad T, Fonarow GC.   +4 more
europepmc   +1 more source

Left atrial appendage thrombi despite oral anticoagulation in transthyretin amyloid cardiomyopathy patients undergoing electrical cardioversion for atrial fibrillation or - flutter. [PDF]

Int J Cardiol Heart Vasc
Poledniczek M, Kronberger C, Gregshammer B, List L, Willixhofer R, Ermolaev N, Duca F, Rettl R, Binder C, Camuz Ligios L, Nitsche C, Eslami M, Graf S, Kastl S, Kastner J, Badr Eslam R, Hengstenberg C, Kammerlander A, Bergler-Klein J.   +18 more
europepmc   +1 more source

Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. [PDF]

Circulation
Fontana M, García-Pavía P, Grogan M, Shah SJ, Engelmann MDM, Hovingh GK, Kristen AV, Lim-Watson MZ, Malling B, Kar S, Revanna M, Sarswat N, Tsujita K, Alexander KM, Maurer MS.   +14 more
europepmc   +1 more source

Wild-Type Transthyretin Amyloid Cardiomyopathy With Bone Marrow Involvement: Clinical Implications of Less Common Sites of Amyloid Deposition. [PDF]

Cureus
Kashiwagi Y, Suzuki K, Yoshinaga T, Sato M, Kawachi K, Ogawa K, Beppu M, Tokuda M.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Transthyretin Amyloid Cardiomyopathy

Journal of the American College of Cardiology
Transthyretin amyloidosis (ATTR-CM) is an infiltrative cardiomyopathy caused by the deposition of amyloid fibrils, leading to heart failure, arrhythmias, and increased mortality. ATTR-CM prevalence is rising. The first disease-modifying drugs have been approved and implemented in Denmark.
Sie Kronborg Fensman, Ali Hussein Jaber Mejren, Tor Skibsted Clemmensen, Steen Hvitfeldt Poulsen   +3 more
semanticscholar   +4 more sources